Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DesRosier Thomas
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer von Moltke Lisa
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shaff Eric D.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henn Matthew R.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer von Moltke Lisa
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henn Matthew R.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DesRosier Thomas
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shaff Eric D.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Young Teresa L.
Seres Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nestlé S.A.(14.29%),Société des Produits Nestlé S.A.(14.29%)
Seres Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner NESTLE SA
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DesRosier Thomas
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer von Moltke Lisa
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henn Matthew R.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shaff Eric D.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Young Teresa L.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ege David S.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Young Teresa L.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ausiello Dennis A
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Berenson Stephen